Clinical Trials Browser

Breast Neoplasms

NCT04954820 2026-06-04

ReLUTH

Phase 2 Recruiting

146 enrolled

EndocrineNET

Neuroendocrine Tumors, Disease Progression

NCT06607692 2026-06-04

LUPARPED

Phase 1/2 Recruiting

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

100 enrolled

EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

56 enrolled

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Phase 1 Recruiting

10 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

70 enrolled

EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

24 enrolled

Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04082520 2026-04-22

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Phase 2 Recruiting

42 enrolled

CNS

Meningioma

NCT05583708 2026-04-22

iPRRT

Phase 2 Recruiting

18 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT05278208 2026-04-13

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase 1/2 Recruiting

65 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

NCT06389097 2026-03-30

(SEEtoTREAT)

Recruiting

80 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

ReLUTH

LUPARPED

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

iPRRT

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

(SEEtoTREAT)